Abstract
Dysfunction of peripheral nerves due to metabolic, toxic, infectious, or genetic causes is a common and debilitating syndrome resulting in sensory loss. Peripheral neuropathies are one of the most widespread neurological disorders, affecting nearly 20 million people in the United States alone. Pharmacologic treatment for peripheral neuropathies is one of the most challenging fields in the clinical research. Sensory neurons are widely distributed and relatively inaccessible to direct drug delivery. Targeted delivery of neurotrophic factors to the primary sensory afferent for treatment of polyneuropathy by gene transfer approach offers the possibility of a highly selective targeted release of bioactive molecules within the nervous system. Preclinical studies with non-replicating herpes simplex virus (HSV)-based vectors injected into the skin to transduce neurons in the dorsal root ganglion (DRG) have demonstrated efficacy in preventing progression of sensory neuropathy without any possible systemic side effects.
Keywords: Diabetes, DRG, gene therapy, growth factors, HSV, peripheral neuropathy.
Current Gene Therapy
Title:Targeted Delivery of Growth Factors by HSV-Mediated Gene Transfer for Peripheral Neuropathy
Volume: 13 Issue: 5
Author(s): Munmun Chattopadhyay
Affiliation:
Keywords: Diabetes, DRG, gene therapy, growth factors, HSV, peripheral neuropathy.
Abstract: Dysfunction of peripheral nerves due to metabolic, toxic, infectious, or genetic causes is a common and debilitating syndrome resulting in sensory loss. Peripheral neuropathies are one of the most widespread neurological disorders, affecting nearly 20 million people in the United States alone. Pharmacologic treatment for peripheral neuropathies is one of the most challenging fields in the clinical research. Sensory neurons are widely distributed and relatively inaccessible to direct drug delivery. Targeted delivery of neurotrophic factors to the primary sensory afferent for treatment of polyneuropathy by gene transfer approach offers the possibility of a highly selective targeted release of bioactive molecules within the nervous system. Preclinical studies with non-replicating herpes simplex virus (HSV)-based vectors injected into the skin to transduce neurons in the dorsal root ganglion (DRG) have demonstrated efficacy in preventing progression of sensory neuropathy without any possible systemic side effects.
Export Options
About this article
Cite this article as:
Chattopadhyay Munmun, Targeted Delivery of Growth Factors by HSV-Mediated Gene Transfer for Peripheral Neuropathy, Current Gene Therapy 2013; 13 (5) . https://dx.doi.org/10.2174/156652321305131212123237
DOI https://dx.doi.org/10.2174/156652321305131212123237 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Medical Treatment for Neurocysticercosis: Drugs, Indications and Perspectives
Current Topics in Medicinal Chemistry Diabetic CVD – Soluble Epoxide Hydrolase as A Target
Cardiovascular & Hematological Agents in Medicinal Chemistry The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Multimodalities Imaging of Immunoglobulin 4-related Cardiovascular Disorders
Current Cardiology Reviews Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Respiratory Tract Manifestations of Rheumatic Diseases in Children
Current Respiratory Medicine Reviews Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Insulin-Degrading Enzyme: Structure-Function Relationship and its Possible Roles in Health and Disease
Current Pharmaceutical Design Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia
Current Medicinal Chemistry Chronic Urticaria: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Aminoacyl-tRNA Synthetases, Indispensable Players in Lung Tumorigenesis
Protein & Peptide Letters Clinical Applications of Autoimmunity to Citrullinated Proteins in Rheumatoid Arthritis, from Improving Diagnostics to Future Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Antileukotriene Drugs: Clinical Application, Effectiveness and Safety
Current Medicinal Chemistry Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Adverse Dermatological Reactions in Rheumatoid Arthritis Patients Treated with Etanercept, an Anti-TNFα Drug
Current Drug Safety Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications
Coronaviruses